Navigation path

Pharmaceuticals - Community Register


Community register of veterinary medicinal products


Product information

Invented name: Oncept IL-2   
Auth. number : EU/2/13/150
Active substance : Feline interleukin-2 recombinant canarypox virus (vCP1338)
ATC: Anatomical main group: QL - Antineoplastic and immunomodulating agents
Therapeutic subgroup: QL03 - Immunostimulants
Pharmacological subgroup: QL03A - Immunostimulants
Chemical subgroup: QL03AX - Other immunostimulants
Chemical substance: QL03AX - Other immunostimulants
(See WHO ATCvet Index)
Indication: Immunotherapy to be used in addition to surgery and radiotherapy in cats with fibrosarcoma (2-5 cm diameter) without metastasis or lymph node involvement in order to reduce the risk of relapse and to increase the time to relapse (local recurrence or metastasis). This was demonstrated in a field trial over a period of 2 years.
Marketing Authorisation Holder: Merial
29 avenue Tony Garnier, 69007 Lyon, France
EPAR and active package presentations

Package presentations

Information about presentations can be found in the website of the European Medicines Agency under the section "Product Information".
Likewise, presentations on which there has been a Commission decision are referred in the Summary of Product Characteristics (Annex I to the Commission Decision granting the marketing authorisation) which is available in the Community Register.

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
07/05/2013 Centralised - Authorisation EMEA/V/C/2562 (2013)2741 of 03/05/2013
24/04/2015 Centralised - Variation EMEA/V/C/2562/IB/1
Updated with Decision(2016)2488 of 20/04/2016
22/04/2016 Centralised - Yearly update (2016)2488 of 20/04/2016
22/03/2018 Centralised - Renewal EMEA/V/C/2562/R/6 (2018)1848 of 20/03/2018